NCT06093841 2025-02-11
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT06479356 2024-08-21
CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2 Recruiting
NCT05259813 2023-11-24
Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 1 Withdrawn
NCT04812691 2023-11-22
CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 1 Completed
NCT06142188 2023-11-21
Relmacabtagene Autoleucel in Hematologic Malignancies
Shanghai Ming Ju Biotechnology Co., Ltd.
Not yet recruiting